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OBJECTIVE: Transarterial chemoembolization is the treatment of choice for intermediate-stage hepatocellular
carcinoma. However, there are no clear data supporting transarterial chemoembolization vs. transarterial
embolization or regarding the best chemotherapeutic agent, which may suggest a preponderant role of
ischemia over chemotherapeutic action. This study sought to evaluate the radiological response and outcome of
transarterial chemoembolization modified by n-butyl cyanoacrylate addition compared to conventional
transarterial chemoembolization in hepatocellular carcinoma patients.
MATERIALS AND METHODS: A retrospective review identified forty-seven patients who underwent modified
chemoembolization and thirty-three who underwent conventional chemoembolization between June 2006 and
December 2011. The radiological response was reassessed using the modified Response Evaluation Criteria in Solid
Tumors. The sustained complete response, time to progression and overall survival rates were also analyzed.
RESULTS: Complete response rates were significantly higher in patients who had undergone modified chemoemboli-
zation compared to those who had undergone conventional treatment (61.7% and 24.3%, respectively; po0.001).
The rate of sustained complete response was significantly higher in the modified chemoembolization group
compared to the conventional chemoembolization group (median of 236 and 37 days, respectively; po0.001). Time to
progression was significantly higher in the modified chemoembolization group compared to the conventional
chemoembolization group (median of 424 and 201 days, respectively; p=0.042). Overall survival rates revealed no
difference between patients who received modified chemoembolization and conventional chemoembolization
(median of 483 and 399 days, respectively; p=0.316).
CONCLUSION: Transarterial chemoembolization modified by n-butyl cyanoacrylate addition was superior to
conventional transarterial chemoembolization in terms of the radiological response in the first imaging control.
Although the sustained complete response and time to progression rates were higher for the modified
chemoembolization group, no differences in overall survival rates were observed.
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Transarterial chemoembolization (TACE) is the treatment
of choice for intermediate-stage hepatocellular carcinoma
(HCC) (1), although this approach is also used for less
advanced cases as a bridge therapy to liver transplantation (2).
However, there are no clear data supporting TACE over
transarterial embolization (TAE) and there is no significant
difference in survival rates between patients who receive
TAE or TACE (3,4). Additionally, no chemotherapeutic agent
has been shown to be better than others in TACE proce-
dures (3). Therefore, the ischemic effect of TACE might be
dominant over the chemotherapeutic effect.
N-butyl cyanoacrylate (NBCA) is a preferred embolic
material for hemorrhage treatment when feasible, due to its
fast preparation and delivery as well as its independenceDOI: 10.6061/clinics/2015(12)04
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from clotting factors to successfully stop bleeding (5). In our
institution, we observed that TACE cases that presented with
intratumoral bleeding during polyvinyl alcohol microsphere
deployment, which were promptly treated with NBCA,
presented better radiological responses compared to those that
underwent conventional TACE (cTACE). For these reasons, in
mid-2010, NBCA was regularly used at the end of every TACE
procedure to definitively exclude the embolized arterial branch
and to theoretically potentiate the ischemic effect of TACE, a
procedure that we termed ‘‘TACE modified by NBCA addition’’
(NBCA-TACE).
Some authors have used NBCA for HCC treatment either
alone or associated with TAE, but to the best of our
knowledge, no studies have compared the treatment group
to a control group or analyzed the radiological response of
treated patients (6–8).
The aim of this study was to analyze the radiological
response, sustained complete response (SCR), time to progres-
sion (TTP) and overall survival (OS) rates in patients with HCC
who had undergone NBCA-TACE compared with cTACE.
’ MATERIALS AND METHODS
Patient selection
This retrospective study included consecutive patients
who had undergone cTACE or NBCA-TACE between 2006
and 2011 with a minimum of 2 years of follow-up and who
met all of the inclusion and exclusion criteria. The study was
approved by the local ethics committee.
The inclusion criteria were as follows: diagnosis of HCC
according to the American Association for the Study of Liver
Diseases guidelines (1) and treatment with cTACE or NBCA-
TACE between 2006 and 2011 at our institution. The exclusion
criteria were as follows: diagnosis of any tumor other than
HCC; failure to proceed in cTACE or NBCA-TACE due to high-
flow arteriovenous fistula; unavailability of multidetector com-
puted tomography (MDCT) or magnetic resonance imaging
(MRI) for review and reassessment before the procedure; and
refusal of patients or family members to have their data
included in this study.
Clinical information
Clinical data were collected from medical records, except the
following information was collected from medical records or
through telephone calls to patients or family: performance of
curative procedures (ablative methods, surgical resection or liver
transplantation) and its realization date; date of death for
deceased patients.
Pre-TACE imaging evaluation, TACE procedure
evaluation and post-TACE imaging evaluation
MDCTs or MRIs that were performed at the time of
diagnosis were reassessed by two dedicated abdominal
radiologists (20 years and 18 years of experience) and the
following information was collected: sum of the largest lesion
diameters; rating the largest lesion in accordance with its largest
diameter (less than 2 cm, 2 to 3 cm, 3 to 5 cm, greater than 5
cm); classification according to number and appearance
(uninodular, multinodular or infiltrative); presence of portal
vein thrombosis; and liver segments with tumors.
TACE patients were reassessed by two experienced inter-
ventional radiologists (12 and 8 years of experience) and the
following information was collected: anatomical hepatic artery
variations according to the classification of Michels (9); cTACE
or NBCA-TACE; presence of intratumoral portal arteriovenous
fistula; and whether technical success was achieved.
All of the MDCTs or MRIs performed after TACE were
reassessed and classified according to the modified response
evaluation criteria in solid tumors (mRECIST) (10) in terms of
complete response (CR), partial response (PR), stable disease
(SD) and progressive disease (PD). CR was defined as the
disappearance of any intratumoral arterial enhancement in all
target lesions; PR was assigned in cases with at least a 30%
decrease in the sum of diameters of viable target lesions
(arterial enhancing lesions), taking as reference the baseline
sum of the diameters of target lesions; SD was defined as any
case that did not qualify for either PR or PD; and PD was
assigned when there was an increase of at least 20% in the sum
of the diameters of viable (enhancing) target lesions, taking as
reference the smallest sum of the diameters of viable target
lesions recorded since treatment started. These results were
used to evaluate the radiological response, SCR, and TTP rates.
Baseline data
Baseline data from the groups are listed in Table 1.
cTACE and NBCA-TACE standardization
In our Institution, all TACE procedures are performed
exclusively by the Interventional Radiology team in a room
dedicated to angiography, usually under local anesthesia.
Interventional procedures were performed using the femoral
approach (11-cm-long 5F sheath introducer) with selective
angiography of the aorta, celiac trunk, common hepatic artery
and superior mesentery artery for tumor feeder characteriza-
tion along with a delay phase for splenoportography using a
5F diagnostic angiography catheter.
The diagnostic angiography catheter used for selective
hepatic artery angiography was irrigated with saline, which
involved a microcatheter (Renegade 18, Boston Scientific,
Natick, Massachusetts, USA) with an inner lumen diameter
of 0.021’’ and a 0.014’’ micro-guidewire (ChoICE, Boston
Scientific) being navigated coaxially until they reach the
supplying arteries of the tumor.
An emulsion containing a maximum of 10 mg mitomycin
diluted in distilled water to a total volume of 20 ml plus 2 ml
iodized oil (Lipiodol, Laboratoire André Guerbet, Aulnay-sous-
Bois, France) was applied through the microcatheter followed by
the application of 300 to 500 micrometer polyvinyl alcohol
microspheres (BeadBlock, Biocompatibles, UK) until stagna-
tion of blood flow and a lack of tumor staining was achieved.
The cTACE was deemed successful when there was no tumor
staining (Figure 1).
In NBCA-TACE, after the steps described above, the
microcatheter was flushed with 5% dextrose solution, followed
by the injection of a mixture of NBCA (Histoacryl, B. Braun AG,
Melsungen, Germany) and iodized oil in a 1:3 to 1:5 ratio
(33%–20% NBCA), depending on the blood flow velocity and
vessel caliber, until the artery was completely obstructed. NBCA-
TACE was successful when all tumor feeders previously
observed were excluded from the circulation (Figure 2).
After the angiographic controls, the introducer sheath was
withdrawn followed by manual compression of the punctured
site until hemostasis was achieved, which lasted for approxi-
mately 15 minutes.
After the procedure, the patients remained in the hospital
for at least 24 hours to control symptoms, and they were then
released.
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Radiological response and SCR, TTP and
OS evaluation
Radiological responses were evaluated using the mRE-
CIST (10); these modified criteria are used to assess HCC
patients who have undergone locoregional or systemic
treatment and have been modified from the response
evaluation criteria in solid tumors (RECIST) (11). mRECIST
classifies the target tumor observed on the first-month
MDCT or MRI as CR, PR, SD or PD.
SCR was defined as the elapsed time since cTACE or
NBCA-TACE until the first evaluated MDTC or MRI was
classified different from CR according to mRECIST. Censored
Table 1 - Baseline data of the groups.
cTACE NBCA-TACE p-value
Number of patients 33 47
Male (%) 26 (78.79) 41 (87.23) 0.365
Age (mean ± sd) 56.4 ± 10.3 58.3 ± 8.9 0.727
Etiology of cirrhosis
Hepatitis B (%) 4 (12.12) 7 (14.89) 1.000
Hepatitis C (%) 13 (39.39) 34 (72.34) 0.005
Alcohol (%) 22 (66.67) 34 (72.34) 0.626
Other causes (%) 1 (3.03) 0 (0.00) 0.412
Aim of TACE
Maintenance in Milan’s criteria (%) 13 (39.39) 24 (51.06) 0.212
Downstaging (%) 13 (39.39) 10 (21.28)
Palliative (%) 7 (21.21) 13 (27.66)
Performance of any curative treatment (%) 10 (30.30) 19 (40.43) 0.479
Performance of new cTACE or NBCA-TACE (%) 16 (48.49) 17 (36.17) 0.192
cTACE or NBCA-TACE per patient (mean ± sd) 1.67 ± 0.89 1.55 ± 0.90 0.580
Laboratory tests
Total bilirubin, in mg/dL (mean ± sd) 1.93 ± 1.52 1.74 ± 0.88 0.117
Albumin, in g/L (mean ± sd) 3.68 ± 0.43 3.53 ± 0.75 0.122
INR (mean ± sd) 1.24 ± 0.19 1.22 ± 0.15 0.163
Alpha-fetoprotein 291.6 ± 731.0 337.4 ± 859.8 0.606
Serum creatinine, in mg/dL (mean ± sd) 0.99 ± 0.32 0.91 ± 0.25 0.085
Serum sodium, in mmol/L (mean ± sd) 139.6 ± 3.7 140,2 ± 3.0 0.422
Sum of the largest diameter of all lesions identified on the basal MDCT or MRI,
in cm (mean ± sd)
6.6 ± 3.8 5.3 ± 2.6 0.185
Largest diameter of the biggest lesion on the basal MDCT or MRI, in cm
o 2.0 cm (%) 2 (6.06) 3 (6.38) 0.207
4 2.0 cm o 3.0 cm (%) 5 (15.15) 14 (29.79)
4 3.0 cm o 5.0 cm (%) 13 (39.39) 16 (34.04)
4 5.0 cm (%) 13 (39.39) 14 (29.79)
Classification in number and aspect
Uninodular (%) 20 (60.61) 31 (65.96) 0.671
Multinodular (%) 12 (36.36) 14 (29.79)
Infiltrative (%) 1 (3.03) 2 (4.26)
Involved hepatic segments
I (%) 1 (3.03) 0 (0.00) 0.412
II (%) 4 (12.12) 7 (14.89) 1.000
III (%) 5 (15.15) 7 (14.89) 1.000
IVa (%) 10 (30.30) 13 (27.66) 0.807
IVb (%) 6 (18.18) 5 (10.64) 0.347
V (%) 9 (27.27) 13 (27.66) 1.000
VI (%) 12 (36.36) 20 (42.55) 0.647
VII (%) 11 (33.33) 14 (29.79) 0.809
VIII (%) 20 (60.61) 23 (48.94) 0.365
Child-Turcotte-Pugh
A (%) 15 (45.45) 26 (55.32) 0.452
B (%) 18 (54.55) 20 (42.55)
C (%) 0 (0.00) 1 (2.13)
BCLC
0 (%) 0 (0.00) 0 (0.00) 0.355
A (%) 19 (57.58) 31 (65.96)
B (%) 11 (33.33) 15 (31.92)
C (%) 2 (6.06) 0 (0.00)
D (%) 1 (3.03) 1 (2.13)
MELD (mean ± sd) 11.55 ± 3.05 10.96 ± 2.77 0.565
Extension of embolization (% of estimated liver volume)
0 to 25 (%) 8 (24.24) 13 (27.66) 0.294
25 to 50 (%) 17 (51.52) 29 (61.70)
50 to 75 (%) 8 (24.24) 4 (8.51)
75 to 100 (%) 0 (0.00) 1 (2.13)
Technical success (%) 30 (90.91) 42 (89.36) 1.000
sd: standard deviation.
783
CLINICS 2015;70(12):781-789 Addition of NBCA to classic TACE in HCC
Monsignore LM et al.
Figure 1 - a-f: cTACE standardization. Selective angiography of the common hepatic artery (a, b) depicts a hypervascular lesion
nourished by distal branches of the hepatic artery (arrows). Microcatheters reached the supplying arteries of the tumor (c). No staining
of the tumor was seen in the final angiography (d, e). The procedure was considered to be successful. The tumor retained Lipiodol and
became radiopaque (f, arrowheads).
Figure 2 - a-f: NBCA-TACE standardization. Selective angiography of the common hepatic artery (a, b) depicts a hypervascular lesion
nourished by distal branches of the hepatic artery (arrows). Microcatheters reached the supplying arteries of the tumor (c). After the
third microcatheterization, with two prior occlusions of smaller distal branches via the application of NBCA-Lipiodol mixture, no
staining of the tumor was seen (d). Application of the NBCA-Lipiodol mixture was performed to definitively occlude that branch and
final angiography showed complete occlusion of the branches directed to the tumor (e). The NBCA-Lipiodol mixture cast inside the
occluded branches is shown by arrowheads (f).
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data included death from any cause, patients who had
undergone any other HCC treatment after the first cTACE or
NBCA-TACE or patients who were lost to follow-up.
TTP was defined as the elapsed time since cTACE or
NBCA-TACE until the first evaluated MDTC or MRI was
classified as PD according to mRECIST. Censored data
included death from any cause, patients who had undergone
any other HCC treatment after the first cTACE or NBCA-
TACE or patients who were lost to follow-up.
OS was defined as the elapsed time from cTACE or NBCA-
TACE until death. Censored data included patients who had
undergone any curative treatment or patients who were lost
to follow up.
Follow-up
The follow-up protocol for patients undergoing TACE at our
institution included obtaining MRI or MDCTcontrols one, three
and six months after the procedure and semiannually thereafter.
In the case of PR or SD, new TACE was proposed according to
the patient’s clinical condition. If the imaging method used for
the control defined PD, a multidisciplinary team decided
whether to perform a new TACE, to use sorafenib or to provide
the best supportive care. In our institution, sorafenib and TACE
have not been used concurrently.
For patients who fit the Milan criteria and achieved
downstaging, liver transplantation was performed in accor-
dance to our health system rules.
Statistical analysis
Continuous data were expressed as the mean ± standard
deviation and analyzed with Student’s t test. The Mann-
Whitney U test was used for ranked data and Fisher’s exact
test was used to assess the association between two
qualitative variables. The Kaplan-Meier method using the
Mantel-Cox test was employed for calculating SCR, TTP and
OS rates. A p-value less than 0.05 was considered statistically
significant. Statistical analysis was performed with IBM s
SPSS s Statistics program, version 20 for Mac.
’ RESULTS
Eighty patients met the inclusion criteria and were
enrolled in the study. Of these, forty-seven patients under-
went NBCA-TACE and thirty-three underwent cTACE.
There were no significant differences in the baseline data
(p40.05) except for hepatitis C virus infection, which was
more frequent in the NBCA-TACE group (p=0.005) and
MDCT, which was more frequent for the cTACE group than
for the NBCA-TACE group in the first imaging control
(po0.001).
Radiological response
Of all the patients, four did not have their first imaging
control analyzed and classified according mRECIST. These
patients included one patient from the cTACE group (patient
passed away before the first imaging control) and three from
the NBCA-TACE group (one underwent a liver transplanta-
tion a few days after the procedure and two patients did not
undergo dynamic MDCT or MRI; one due to clinical con-
traindication and the other due to patient refusal, thus not
amenable to analysis). For the cTACE group, the response
analysis of the target lesion according to the mRECISTcriteria
revealed 24.3% of patients with CR, 54.6% with PR, 12.1%
with SD, 6.1% with PD and 3.0% who were not amenable for
analysis. For the NBCA-TACE group, this distribution was
61.7% with CR, 23.4% with PR, 4.3% with SD, 4.3% with PD
and 6.4% who were not amenable for analysis (po0.001).
These data are summarized in Table 2.
Sustained complete response
The NBCA-TACE group demonstrated a significantly
longer SCR compared to the cTACE group. The NBCA-
TACE group had an estimated mean and median SCR
of 360.65 and 236 days, respectively, while the cTACE group
had an estimated mean and median of 120.8 and 36 days,
respectively, with a significant difference in Kaplan-Meier
curves according to the Mantel-Cox test (po0.001)
(Figure 3).
Time to progression
The NBCA-TACE group demonstrated a significantly
longer TTP compared to the cTACE group. The NBCA-
TACE group had an estimated mean and median TTP of
484.5 and 424 days, respectively, while the cTACE group had
an estimated mean and median of 253.9 and 201 days,
respectively, with a significant difference in Kaplan-Meier
curves according to the Mantel-Cox test (p=0.042) (Figure 4).
Overall survival
The mean and median estimated OS rates of the cTACE
group were 470.49 and 399 days, respectively, while in the
NBCA-TACE group, these values were 613.97 and 502 days,
respectively. There were no significant differences between
groups according to the Mantel-Cox test (p=0.316) (Figure 5).
Table 2 - Findings in the first imaging control post TACE.
cTACE NBCA-TACE p-value
Type of exam in the first control post TACE
MDCT (%) 13 (39.39) 3 (6.38) o 0.001
MRI (%) 19 (57.58) 43 (91.49)
Unperformed (%) 1 (3.03) 1 (2.13)
Elapsed time between TACE and first control exam, in days (mean ± sd) 41.72 ± 22.52 38.63 ± 20.89 0.367
mRECIST classification of target lesion in first control exam
CR (%) 8 (24.24) 29 (61.70) 0.001
PR (%) 18 (54.55) 11 (23.40)
SD (%) 4 (12.12) 2 (4.26)
PD (%) 2 (6.06) 2 (4.26)
Impossible to evaluate (%) 1 (3.03) 3 (6.38)
sd: standard deviation.
785
CLINICS 2015;70(12):781-789 Addition of NBCA to classic TACE in HCC
Monsignore LM et al.
Complications and post-procedure side effects
There were no differences between the rates of post-
embolization syndrome symptoms in both the cTACE and
NBCA-TACE groups; abdominal pain was the major presented
symptom followed by nausea, fever and vomiting (Table 3).
’ DISCUSSION
TACE is employed worldwide for the treatment of inter-
mediate HCC, which is characterized by no severe compromise
in liver function (Child A or B), multinodular disease and no
Figure 3 - Kaplan-Meier curve of SCR of patients undergoing cTACE and NBCA-TACE.
Figure 4 - Kaplan-Meier curve of TTP of patients undergoing cTACE and NBCA-TACE.
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signs of vascular invasion or extra hepatic spread (12). In
addition, TACE has been used not only in patients with early-
stage HCC but also as a bridge to transplant (13) and in
advanced disease stages, in association with other therapies (14).
The use of different chemotherapeutic agents and diverse
embolic materials worldwide makes cTACE a non-standar-
dized procedure. Although the introduction of doxorubicin-
eluting beads in TACE (DEBDOX-TACE) standardized this
procedure, no clear benefits in terms of tumor response or
survival have been observed (15,16).
Despite its inclusion in the algorithm of HCC treatment
(1,17), TACE has not yet been demonstrated to be superior over
TAE for survival (3,4). The lack of evidence showing superiority
of one chemotherapeutic agent over the other in TACE
procedures (3), as well as the absence of superiority of TACE
over TAE, may suggest a preponderance of the ischemic effect
over the chemotherapeutic effect. Approximately 90% of the
HCC blood supply originates from the hepatic artery, while
only 10% is from the portal vein, although the normal liver
depends on approximately 25% of nutrients coming through
the hepatic artery and 75% through the portal vein (18), which
could explain this possible preponderance of the ischemic effect
of TACE. Some authors suggest that further studies are needed
to evaluate the impact of maximization of ischemia in TACE on
HCC patients (3).
To our knowledge, there are only three reports on the use
of NBCA in TAE in HCC patients using different techniques
as an alternative to cTACE in the English literature (6–8).
However, there was no cTACE group as a control in any of
these studies and none of the studies assessed tumor
response using imaging methods. Berghammer P et al. (6)
performed a retrospective analysis to evaluate the use of a
Lipiodol-NBCA mixture alone in 16 patients with unresect-
able HCC and observed few side effects with no survival
benefit (median survival of 8.5 months). Loewe C et al. (7)
retrospectively studied 36 patients with unresectable HCC
embolized with a Lipiodol-NBCA mixture alone and
observed a median survival of 26 months, which was
potentially prolonged compared to reports of other emboli-
zation techniques in the literature. In a retrospective study
including 46 patients with unresectable HCC, Rand T et al. (8)
studied embolization with Trisacryl microspheres followed
by a Lipiodol-NBCA mixture to definitively occlude the em-
bolized territory; however, this study did not use any
chemotherapeutic agent. These authors observed a median
survival of 666 days after diagnosis, similar to other tech-
niques described in the literature.
Regarding the tumor response assessed by mRECIST, three
studies were found in the literature that compared cTACE to
DEBDOX-TACE. In 2011, Song MJ et al. (19) published a
retrospective controlled study with 40 HCC patients who had
undergone cTACE using doxorubicin as a chemotherapeutic
agent or DEBDOX-TACE. These authors observed a signifi-
cant difference in the objective response (CR plus PR) in
imaging controls one month after the procedures (p=0.001).
The authors found the following distribution for CR, PR and
SD: cTACE 20%, 10% and 70%; and DEBDOX-TACE 35%,
50% and 15%, respectively. In 2012, Song MJ et al. (20)
published a retrospective cohort including 129 patients with
Figure 5 - Kaplan-Meier curve of OS of patients undergoing cTACE and NBCA-TACE.
Table 3 - Post embolization symptoms and complications.
cTACE NBCATACE p-value
Nausea (%) 2 (6.06) 4 (8.51) 1.000
Vomiting (%) 1 (3.03) 1 (2.13) 1.000
Abdominal pain or discomfort (%) 8 (24.24) 17 (36.17) 0.330
Fever (%) 3 (9.09) 1 (2.13) 0.301
Other symptoms or complications (%) 3 (9.09) 0 (0.00) 0.066
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HCC who had undergone cTACE using doxorubicin as a
chemotherapeutic agent or DEBDOX-TACE. The imaging
control that was assessed for mRECIST evaluation was
taken 3 months after the procedure. The DEBDOX-TACE
group presented as 55.0% CR, 26.6% PR, 15.0% SD and 3.4%
PD, while the cTACE group presented as 23.1% CR, 26.3%
PR, 30.4% SD and 20.2% PD. The difference between groups
was significant at po0.001. Malagari K et al. (21) performed
a prospective study including HCC patients who were
classified as BCLC A with unresectable lesions or lesions
that were not amenable for percutaneous ablation and were
classified as BCLC B. All of the patients were scheduled for
three sessions of DEBDOX-TACE unless CR was achieved
in fewer sessions. Imaging controls were performed 30 days
after the last procedure and assessed by mRECIST. These
authors observed the following results in the evaluation of
target lesions: 22.2% CR, 46.6% PR, 22.2% SD and 8.8% PD.
In the present study, the radiological response assessed by
mRECIST for the NBCA-TACE group was better in comparison
to any other study, with 61.7% CR, 23.4% PR and 4.3% SD; these
results were also superior to those observed for the cTACE
group, with 24.3% CR, 54.6% PR and 12.1% SD (Figure 6).
Despite the fact that there was no increase in the OS rate of
the NBCA-TACE group compared with the cTACE group or
even in the use of NBCA for HCC embolization in other
studies (6–8), we observed a significant increase in the SCR
and TTP rates of the NBCA-TACE group compared to the
cTACE group, which may lengthen the waiting time for liver
transplantation within the Milan criteria. This finding also
demonstrates the superiority of NBCA-TACE in terms of the
radiological responses and may consequently result in higher
down-staging rates in selected HCC patients.
Our study has several limitations. First, this was a retrospective
study examining preliminary results with a small number of
patients who had been divided into two heterogeneous but
comparable groups. Second, this study was performed by
experienced interventional radiologists in a single center, which
may have biased the results. Third, as NBCA-TACE is a new
procedure with an embolic material that is different from what
has been previously used, there may have been a learning curve
that could have distorted the results, although this technique is
already routinely used by staff in other environments.
In conclusion, NBCA-TACE was superior to cTACE in terms
of the radiological response and SCR and TTP in HCC patients,
with no difference regarding OS in the studied groups. Future
prospective randomized controlled studies with larger cohorts
are required to confirm our findings.
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